# Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06367088/  
OnCo record `nct06367088` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.

## Summary

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06367088 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 27 participants, started 2024-05-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: Cadonilimab. Conditions listed: Triple-negative Breast Cancer; Cadonilimab. Triple-negative eligibility wording from the registry: "* Recurrent or metastatic TNBC patients;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06367088
- Phase: 2
- Setting: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT06367088: https://clinicaltrials.gov/study/NCT06367088

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06367088.json